Geode Capital Management
APUS icon

Geode Capital Management’s Apimeds Pharmaceuticals US APUS Stock Holding History

Geode Capital Management’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-3,511
Closed -$31.6K – 4552
2026
Q2 		$31.6K Sell
3,511
-494
-12% -$6.73K ﹤0.01% 4316
2026
Q1 		$71.7K Buy
4,005
+516
+15% +$8.31K ﹤0.01% 4224
2025
Q4 		$57.2K Buy
3,489
+414
+13% +$8.83K ﹤0.01% 4209
2025
Q3 		$54.7K Buy
+3,075
New +$57K ﹤0.01% 4271

Other funds holding APUS

HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Hemenway Trust Hemenway Trust
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.42B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Ankerstar Wealth
Ankerstar Wealth Leander, Texas $129M AUM 9.28% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Geode Capital Management's APUS Position: Q3 2026 in Review

Geode Capital Management sold out of Apimeds Pharmaceuticals US (APUS) in Q3 2026, closing a stake of 3,511 shares — an estimated $31.6K sold.

Geode Capital Management first reported a position in APUS in Q3 2025 and held it in 4 quarters. The position peaked at $71.7K in Q1 2026. 8 funds tracked by Wall St. Rank hold APUS as of Q3 2026.

  • Geode Capital Management reported no remaining Apimeds Pharmaceuticals US position as of Q3 2026 after selling out during the quarter.
  • Geode Capital Management sold 3,511 Apimeds Pharmaceuticals US shares in Q3 2026, an estimated $31.6K.
  • Geode Capital Management first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and held it in 4 quarters.
  • Geode Capital Management's Apimeds Pharmaceuticals US position peaked at $71.7K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.